by John Conrad | Dec 18, 2024 | iBIO in the News
iBIO President & CEO John Conrad recently had the pleasure of chatting with Kyle LaHucik to discuss the exciting developments in our biotech ecosystem. Many of you may have already seen his excellent article published yesterday in Endpoints News, which provides a...
by John Conrad | Dec 18, 2024 | iBIO News
As Illinois’ life sciences industry continues its remarkable growth trajectory, iBIO President and CEO John Conrad and iBIO Board Chair Ken Johnson, Senior Vice President of Global Development and Medical Affairs at Xeris Pharmaceuticals, sat down to discuss the...
by John Conrad | Dec 12, 2024 | Member News, NewsBrief
In a significant move addressing one of healthcare’s most pressing challenges, Meitheal Pharmaceuticals has secured exclusive U.S. commercial rights to XENLETA® (lefamulin acetate). The timing couldn’t be more critical: between now and 2050, antibiotic...
by John Conrad | Dec 3, 2024 | Member News
COUR Pharmaceuticals has secured a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize its tolerogenic nanoparticle treatments for autoimmune conditions. The partnership, announced via press release...
by John Conrad | Dec 2, 2024 | iBIO News
The newly released TECONOMY/BIO report, “The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions,” paints an impressive picture of Illinois’ life sciences industry. The data reveals an industry that’s not just...
